8-K: RadNet Posts Record Q4 Revenue, EBITDA; Eyes Strong 2026 Growth with AI

RadNet, Inc. reported record fourth-quarter 2025 revenue and Adjusted EBITDA, driven by strong procedural growth and strategic AI investments, while issuing robust 2026 financial guidance.

Summary

• RadNet achieved record Total Company Revenue of $547.7 million in Q4 2025, a 14.8% increase from Q4 2024.
• Total Company Adjusted EBITDA reached a record $87.7 million in Q4 2025, up 16.9% year-over-year, with margins improving to 16.0%.
• Digital Health segment revenue grew 48.2% to $27.9 million in Q4 2025, with Adjusted EBITDA increasing 8.9% to $4.9 million.
• Aggregate advanced imaging procedural volumes (MRI, CT, PET/CT) increased 14.1% in Q4 2025, with same-center volumes up 9.6%.
• For full-year 2025, Total Company Revenue was $2,040.2 million (up 11.5%) and Adjusted EBITDA was $300.2 million (up 7.4%).
• Full-year 2025 GAAP Net Loss was $(18.7) million, compared to Net Income of $2.8 million in 2024, primarily due to unusual or one-time items and significant investments.
• RadNet provided 2026 guidance anticipating Imaging Center segment Revenue growth of 17%-19%, Adjusted EBITDA growth of 18%-22%, and Free Cash Flow growth of 29%-41%.
• Digital Health segment 2026 guidance projects Revenue growth of 46%-56% and Annual Recurring Revenue (ARR) to approach or exceed $140 million by year-end 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating robust operational performance, strategic growth through acquisitions and AI investments, and confident forward guidance, despite a GAAP net loss attributed to significant investments and one-time items.

Positives

• Record Total Company Revenue of $547.7 million in Q4 2025, a 14.8% increase.
• Record Total Company Adjusted EBITDA of $87.7 million in Q4 2025, a 16.9% increase.
• Adjusted EBITDA margins improved by 29 basis points to 16.0% in Q4 2025.
• Digital Health segment revenue surged 48.2% to $27.9 million in Q4 2025.
• Strong aggregate advanced imaging procedural volume growth of 14.1% in Q4 2025.
• Robust same-center advanced imaging procedural volume growth of 9.6% in Q4 2025.
• Imaging Center segment exceeded 2025 Revenue and Adjusted EBITDA guidance levels.
• 2026 guidance projects significant growth: Imaging Center Revenue 17%-19%, Adjusted EBITDA 18%-22%, Free Cash Flow 29%-41%.
• Digital Health 2026 guidance anticipates 46%-56% Revenue growth and ARR exceeding $140 million.
• Acquisition of Gleamer enhances the Digital Health division with a comprehensive suite of clinical AI solutions.
• Anticipates a minimum of four FDA clearances in 2026 for radiology clinical AI solutions.
• Increasing demand for services and focus on improving patient-throughput and capacity.

Negatives

• Adjusted Earnings Per Share decreased to $0.23 in Q4 2025 from $0.24 in Q4 2024.
• Reported a Total Company Net Loss of $(0.6) million in Q4 2025, compared to Net Income of $5.3 million in Q4 2024.
• Reported a Total Company Net Loss of $(18.7) million for full-year 2025, compared to Net Income of $2.8 million in 2024.
• Fully diluted Net Loss Per Share was $(0.01) in Q4 2025 and $(0.25) for full-year 2025.
• Higher Capital Expenditures for the Imaging Center segment in 2025 ($170.5 million) exceeded revised guidance ($157-$167 million).
• Higher Non-Capitalized R&D for the Digital Health segment in 2025 ($20.2 million) exceeded revised guidance ($18-$20 million).
• Anticipated headwinds in 2026 guidance from projected increases in same-center labor costs.
• Impact of severe winter weather conditions experienced in January and February 2026.

Risks

• Changes in general economic conditions nationally and regionally, including effects on labor costs and availability.
• Ability to service indebtedness, make principal and interest payments, comply with debt covenants, and refinance debt on acceptable terms.
• Availability and terms of capital to fund business expansion and facility improvements.
• Ability to maintain current credit rating and the impact on funding costs and competitive position if not maintained.
• Volatility in interest and exchange rates, or credit markets.
• Adequacy of cash flow and earnings to fund current and future operations.
• Changes in service mix, revenue mix, and procedure volumes.
• Delays in receiving payments for services provided.
• Increased bankruptcies among partner physicians or joint venture partners.
• Impact of the political environment and related developments on the healthcare marketplace, including the future of the Affordable Care Act.
• Extent to which healthcare reform, new legislation, regulations, or litigation reduce coverage or reimbursement rates for services.
• Closures or slowdowns and changes in labor costs and labor difficulties, including stoppages.
• Occurrence of hostilities, political instability, or catastrophic events.
• Emergence or reemergence of and effects related to future pandemics, epidemics, and infectious diseases.
• Noncompliance with privacy or security laws or any cybersecurity incident or breach involving confidential information.

Future Outlook

RadNet anticipates strong growth in 2026, with Imaging Center segment revenue projected to increase by 17%-19% and Adjusted EBITDA by 18%-22%. The Digital Health segment is expected to see revenue growth of 46%-56%, driven by sales of AI-powered solutions and contributions from recent acquisitions like Gleamer. The company plans significant infrastructure investments in Digital Health sales, marketing, and implementation teams and expects a minimum of four FDA clearances for its AI solutions in 2026.

Management Comments

• "I am very pleased with the fourth quarter performance. Relative to last year's fourth quarter, Total Company Revenue increased 14.8% and Adjusted EBITDA increased 16.9%, resulting in margin improvement of 29 basis points."
• "This performance was driven by strong aggregate and same center procedural growth, combined with a continued focus on driving operating and clinical efficiencies within the Imaging Center segment."
• "During the fourth quarter, we continued to experience increasing demand for our services in virtually all core markets, and operations teams were focused on improving patient-throughput and driving capacity at existing centers."
• "Moving into 2026, RadNet is well-positioned to accelerate growth within Digital Health. With the addition of products resulting from this morning's acquisition of Gleamer in Paris, France, the Digital Health division now includes what we believe to be the most comprehensive and broad collection of clinical AI solutions of any company worldwide."
• "The diagnostic imaging industry will transform in the coming years as a result of an industry-wide adoption of the kind of AI-powered workflow and clinical tools that RadNet is acquiring, developing, utilizing and commercializing."
• "We intend to continue to develop and bring-to-market solutions that address the critical challenges the industry faces, including labor shortages, capacity constraints and the inability of radiologists to keep pace with growing industry volumes, all in an effort to improve patient care and outcomes."
• "Within the Imaging Center segment, we expect 2026 performance to benefit from the contribution of continued increases in same-center performance, further tuck-in acquisitions, reimbursement efforts driving more favorable pricing and de novo center openings."
• "Despite the continued focus it takes to invest in building the infrastructure of the business, 2026 Digital Health guidance implies growth of Revenue between 45% and 55% from 2025 full-year performance."

Industry Context

StockSavvy.ai notes that RadNet's strong performance and aggressive expansion into AI-powered diagnostic solutions align with the broader healthcare industry trend of leveraging technology to enhance efficiency, address labor shortages, and improve patient outcomes. The acquisition of Gleamer positions RadNet as a leader in clinical AI, a rapidly growing segment within diagnostic imaging, potentially setting a benchmark for competitors seeking to integrate advanced AI into their operations.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against global industry standards. StockSavvy.ai cannot provide a detailed comparison without this information.

Stakeholder Impact

• Shareholders: Positive impact due to record revenue and Adjusted EBITDA, strong procedural growth, exceeding 2025 guidance for key metrics, and robust 2026 growth projections, though tempered by a GAAP net loss.
• Employees: DeepHealth technology solutions aim to increase productivity and decrease exposure to challenging labor markets, potentially impacting roles and workflows.
• Customers/Patients: Expected to benefit from improved automation, advanced clinical and operational capabilities, leading to more favorable patient care and health outcomes.
• Referring Physicians: Anticipated improved service levels due to technological advancements and capacity expansion.
• Health System Partners: Expect further alignment with RadNet's strategic initiatives.
• Insurance Plans and Other Payors: Anticipated closer relationships due to improved service levels and cost-effectiveness.

Next Steps

• Continue implementing DeepHealth technology solutions (TechliveTM, See-Mode) internally.
• Develop and bring-to-market AI solutions addressing industry challenges like labor shortages and capacity constraints.
• Seek a minimum of four FDA clearances during 2026 for radiology clinical AI solutions.
• Make significant infrastructure investments in 2026 to build Digital Health sales, marketing, and implementation teams.
• Host a conference call on March 2, 2026, at 10:30 a.m. ET to discuss Q4 and full-year 2025 results.

Key Dates

Recommendation

The filing demonstrates exceptional growth in both the core imaging business and the high-growth Digital Health segment, driven by strategic AI investments and acquisitions. RadNet exceeded its own upwardly revised 2025 guidance for key metrics and provided very strong 2026 guidance. While a GAAP net loss was reported, it is largely attributable to significant strategic investments and one-time items, which are expected to fuel future growth. The company's leadership in clinical AI and its focus on addressing critical industry challenges position it for continued market outperformance.

Keywords

RadNet, RDNT, diagnostic imaging, medical imaging, AI, artificial intelligence, DeepHealth, clinical AI, radiology, outpatient imaging, healthcare technology, financial results, earnings, EBITDA, revenue, procedural volumes, 8-K, SEC filing, 2025 results, 2026 guidance, Gleamer acquisition